Emerging Biopharma

obesity drugs
Biotech

MindRank reports 10% weight loss on oral GLP-1 drug in phase 2b

The Chinese phase 2b obesity trial suggests efficacy is in the same ballpark as Eli Lilly’s orforglipron but MindRank's drug was given twice a day.
Nick Paul Taylor Jun 24, 2025 10:06am
china chinese Asia

Corxel, Sciwind post data as China's obesity push gathers pace

Jun 23, 2025 9:20am
red and purple piggy banks

Syncona cites 'challenging' market for switching investment plan

Jun 20, 2025 6:00am
dynamic arrows moving up

US biotechs must adapt as global competition rises: Antares CEO

Jun 17, 2025 8:15am
Astellas

Astellas offers lab space to help Japanese biotechs 'go global'

Jun 13, 2025 4:41am
finance numbers tape money

Novo Nordisk inks $812M Deep Apple deal to pursue obesity target

Jun 11, 2025 7:00am
More News

Juri inks $210M T-cell engager deal with China biotech

May 27, 2025 6:00am

Nominations now open for Fierce Biotech's 2025 Fierce 15

May 20, 2025 7:30am

Stylus outlines next-gen gene editing mission with $85M in hand

May 13, 2025 7:00am

Former Inhibikase CEO launches new biotech for Parkinson's asset

May 12, 2025 12:44pm